Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US.

PT Bio Farma will manufacture 20 million doses of the vaccine this year.

Additionally, the company will produce another 100 million vaccine doses by 2024.

A recombinant protein-based Covid-19 vaccine, IndoVac received EUA in the country as a primary shot in adult patients.

The primary series shots comprise approximately 80% of the content that is obtained locally.

Licenced from Baylor College of Medicine’s integrated commercialisation team, BCM Ventures, IndoVac received approval after a thorough product and clinical development approach.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Indonesia is pursuing halal certification for IndoVac as its production did not utilise any animal cells or products.

IndoVac has concluded an audit from the Indonesian Ulema Council Food and Drug Analysis Agency, and the Halal Certification Agency of the Religious Affairs Ministry is anticipated to grant approval soon.

Texas Children’s Hospital Center for Vaccine Development co-director Dr Maria Elena Bottazzi said: “The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the Covid-19 pandemic.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma intends to supply the IndoVac vaccine abroad to aid other countries in need and contribute to worldwide vaccine equality.